FDA's draft guidance on data for sunscreen ingredient GRASE determinations overly focuses on risks relative to benefits, potentially shortchanging consumers at a time of soaring skin cancer rates, according to manufacturers, physicians and public health advocates.
FDA extended the comment deadline through Feb. 23 and was pointed about soliciting feedback regarding its draft guidance...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?